Dupilumab Efficacy in Adolescent Atopic Dermatitis
Key Findings
Dupilumab achieved clear/almost clear skin in 42% of adolescents by week 16. Significant improvement in itch and quality of life.
Summary
Dupilumab achieved clear/almost clear skin in 42% of adolescents by week 16. Significant improvement in itch and quality of life.
Study Design
Phase 3 trial in 350 adolescents (12-17 years) with moderate-to-severe atopic dermatitis inadequately controlled by topicals.
Methods
Subcutaneous dupilumab vs placebo for 16 weeks. Primary endpoints: IGA 0/1 and EASI-75 at week 16.
Results
IGA 0/1: 42% vs 8% (p<0.001). EASI-75: 67% vs 19%. Peak pruritus NRS reduction: 47% vs 18%.
Conclusions
Dupilumab demonstrates strong efficacy and safety in adolescents, offering systemic alternative to topical therapies.
Full Abstract
This study examined dupilumab efficacy in adolescent atopic dermatitis in a comprehensive clinical investigation.